Integrated DNA Technologies Bolsters Comprehensive Genomic Profiling Solutions With Launch of New Archer™ HRD Technology for Cancer Research

Archer CGP research assays now enable homologous recombination deficiency (HRD) assessment for identification of key biomarkers critical for cancer research

With a history of driving innovation and collaboration in next generation sequencing (NGS), Integrated DNA Technologies is expanding its Archer portfolio of comprehensive genomic profiling (CGP) solutions to include homologous recombination deficiency (HRD) assessment. Available as a standalone assay, spiked-in as a supplementary module or integrated in an Archer NGS panel, the new HRD module complements existing Archer microsatellite (MSI) and tumor mutational burden (TMB) assessment capabilities to create a flexible, customizable CGP solution for labs looking to optimize sequencing resources. The HRD assessment is available via the:

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240905361882/en/

With a history of driving innovation and collaboration in next generation sequencing (NGS), Integrated DNA Technologies is expanding its Archer portfolio of comprehensive genomic profiling (CGP) solutions to include homologous recombination deficiency (HRD) assessment. (Photo: Business Wire)

• VARIANTPlex™ HRD Module—available as a spike-in to other Archer panels or ran alone.
• VARIANTPlex™ Complete Solid Tumor v2 panel—expands Archer’s existing Complete Solid Tumor panel, now capable of assessing HRD.
• VARIANTPlex™ Pan Solid Tumor v2 panel—expands Archer’s existing Pan Solid Tumor panel, now capable of assessing HRD.

Powered by Archer’s Anchored Multiplex PCR (AMP™) chemistry and Archer Analysis, the new HRD module and updated Archer NGS panels enable downstream applications of precision medicine, provides a differentiated solution that can be customized to fit a lab’s solid tumor research needs, and expands Archer’s existing CGP portfolio.

“With our new HRD module, IDT is enabling labs to unlock the most comprehensive biomarker content from a single, low-input sample,” said Steve Wowk, Vice President/General Manager, Gene Reading Business Unit at IDT. “As a trusted cancer research partner, IDT is continuously innovating on its cancer research solutions to equip labs with the timely, accurate and relevant answers they need about cancer, while helping them overcome the challenges they face with technical and resource constraints. With CGP on-market solutions currently a one-size-fits-all, we’re excited to make our HRD module available as a custom CGP solution, building on our commitment to accelerate the pace of genomics by broadly enabling CGP to advance cancer research.”

As comprehensive genomic profiling for solid tumors grows in popularity to rapidly identify cancer biomarkers, IDT’s suite of CGP solutions is designed to fit labs unique needs with pre-designed RNA- and DNA-based panels, customizable panels, and supplementary modules to easily target key genomic signatures like MSI, TMB, and HRD. IDT’s CGP solution allows labs to adjust targets quickly without significant changes to established protocols.

To learn more about HRD assessment capabilities and IDT Archer’s CGP solutions, visit https://www.idtdna.com/CGP.

About IDT

For more than 35 years, Integrated DNA Technologies, Inc. (IDT) has empowered genomics laboratories with an oligonucleotide manufacturing process unlike anyone else in the industry, featuring the most advanced synthesis, modification, purification, and quality control capabilities available. Since its founding in 1987, IDT has progressed from a leading oligo manufacturer to a genomics solutions provider supporting key application areas such as next generation sequencing, CRISPR genome editing, synthetic biology, digital PCR, and RNA interference. IDT manufactures products used by scientists researching many forms of cancer and most inherited and infectious diseases.

Seeking to fulfill its mission of accelerating the pace of genomics, IDT acquired Archer™ NGS Research Assays in December 2022. When combined with its existing solutions, the expanded portfolio helps realize the shared vision of enabling researchers to rapidly move from the lab to life-changing advances.

IDT’s infrastructure supports customers around the globe with its manufacturing headquarters situated in Coralville, Iowa, USA, with additional manufacturing sites in San Diego, California, USA; Boulder, Colorado, USA; Research Triangle Park, North Carolina, USA; Ann Arbor, Michigan, USA; Leuven, Belgium; and Singapore.

IDT is proud to be part of Danaher. Danaher’s science and technology leadership puts IDT’s solutions at the forefront of the industry, so they can reach more people. Being part of Danaher means we can offer unparalleled breadth and depth of expertise and solutions to our customers.

Together with Danaher’s other businesses across Biotechnology, Diagnostics and Life Sciences, we unlock the transformative potential of cutting-edge science and technology to improve billions of lives every day.

For more information about IDT, visit www.idtdna.com and follow the company on LinkedIn, X, Facebook, YouTube, and Instagram.

Disclaimer: RUO — For research use only. Not for use in diagnostic procedures. Unless otherwise agreed to in writing, IDT does not intend these products to be used in clinical applications and does not warrant their fitness or suitability for any clinical diagnostic use.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240905361882/en/